GSA Capital Partners LLP decreased its position in Luminex Co. (NASDAQ:LMNX) by 62.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 73,959 shares of the medical instruments supplier’s stock after selling 123,043 shares during the period. GSA Capital Partners LLP owned about 0.17% of Luminex worth $1,504,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Pinebridge Investments L.P. lifted its position in Luminex by 8.3% during the second quarter. Pinebridge Investments L.P. now owns 5,266 shares of the medical instruments supplier’s stock valued at $111,000 after buying an additional 405 shares during the period. First Quadrant L P CA purchased a new position in shares of Luminex in the 3rd quarter worth about $173,000. Sei Investments Co. raised its position in shares of Luminex by 38.7% in the 2nd quarter. Sei Investments Co. now owns 8,245 shares of the medical instruments supplier’s stock worth $174,000 after purchasing an additional 2,299 shares during the last quarter. SG Americas Securities LLC raised its position in shares of Luminex by 37.4% in the 2nd quarter. SG Americas Securities LLC now owns 9,726 shares of the medical instruments supplier’s stock worth $205,000 after purchasing an additional 2,649 shares during the last quarter. Finally, Crossmark Global Holdings Inc. purchased a new position in shares of Luminex in the 3rd quarter worth about $254,000. 79.16% of the stock is owned by institutional investors.
LMNX has been the subject of several recent analyst reports. Jefferies Group reaffirmed a “hold” rating and issued a $21.00 price target on shares of Luminex in a research report on Friday, October 20th. TheStreet raised Luminex from a “c+” rating to a “b-” rating in a research report on Wednesday, November 1st. BidaskClub downgraded Luminex from a “hold” rating to a “sell” rating in a report on Wednesday, December 6th. Finally, BTIG Research started coverage on Luminex in a report on Friday, January 5th. They issued a “buy” rating and a $24.00 price objective for the company. Two research analysts have rated the stock with a sell rating, four have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $20.80.
In other news, Director G Walter Loewenbaum II sold 10,503 shares of the company’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $20.61, for a total transaction of $216,466.83. Following the sale, the director now directly owns 564,217 shares of the company’s stock, valued at approximately $11,628,512.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders sold 131,698 shares of company stock worth $2,761,201. 6.90% of the stock is owned by insiders.
Shares of Luminex Co. (LMNX) traded up $0.04 during trading hours on Thursday, hitting $20.50. The company had a trading volume of 143,457 shares, compared to its average volume of 288,582. The company has a market cap of $896.51, a P/E ratio of 30.60, a PEG ratio of 1.96 and a beta of 0.19. Luminex Co. has a 52 week low of $17.68 and a 52 week high of $22.42.
Luminex (NASDAQ:LMNX) last posted its quarterly earnings results on Monday, October 30th. The medical instruments supplier reported $0.25 EPS for the quarter, topping the Zacks’ consensus estimate of $0.19 by $0.06. Luminex had a return on equity of 6.01% and a net margin of 9.52%. The company had revenue of $74.14 million for the quarter, compared to analysts’ expectations of $74.38 million. During the same period in the previous year, the firm earned $0.21 EPS. The firm’s revenue was up 4.1% compared to the same quarter last year. sell-side analysts expect that Luminex Co. will post 0.49 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 12th. Investors of record on Friday, December 22nd will be issued a $0.06 dividend. The ex-dividend date of this dividend is Thursday, December 21st. This represents a $0.24 dividend on an annualized basis and a yield of 1.17%. Luminex’s dividend payout ratio is presently 35.82%.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/11/luminex-co-lmnx-holdings-cut-by-gsa-capital-partners-llp.html.
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.